Intas and Arecor have announced that they are collaborating on developing value added medicines, after striking an exclusive licensing deal that will see the pair use Arecor’s proprietary Arestat formulation technology to develop an unspecified reformulated product, with a particular focus on making it suitable to be used by patients outside of the hospital setting.
Announcing the deal – financial terms of which were not disclosed – Intas said the collaboration “will see the development...





